# Immucell Corp: financial statements, quarterly

ICCC · Nasdaq · CIK 811641 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/iccc.md) · [Financials](/companies/iccc/financials.md) · [Filings](/companies/iccc/filings.md) · [Insiders](/companies/iccc/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/iccc/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [5.4](/filings/0001213900-23-086092.md) | [0.0 d](/filings/0001213900-24-028718.md) | [7.3](/filings/0001213900-25-043287.md) | [5.5](/filings/0001213900-25-076635.md) | [6.0](/filings/0001437749-25-034817.md) | [7.8 d](/filings/0001437749-26-010339.md) | [8.1](/filings/0001437749-26-017045.md) | [6.4](/filings/0001437749-26-027668.md) | [5.5](/filings/0001437749-25-034817.md) | [7.6 d](/filings/0001437749-26-010339.md) | [10.4](/filings/0001437749-26-017045.md) | [7.2](/filings/0001437749-26-027668.md) |
| Cost of revenue | $m | [4.1](/filings/0001213900-24-097450.md) | [0.0 d](/filings/0001013762-25-004072.md) | [5.0](/filings/0001213900-25-043287.md) | [4.2](/filings/0001213900-25-076635.md) | [4.4](/filings/0001437749-25-034817.md) | [4.9 d](/filings/0001437749-26-010339.md) | [4.7](/filings/0001437749-26-017045.md) | [3.6](/filings/0001437749-26-027668.md) | [3.1](/filings/0001437749-25-034817.md) | [4.7 d](/filings/0001437749-26-010339.md) | [5.7](/filings/0001437749-26-017045.md) | [4.7](/filings/0001437749-26-027668.md) |
| Gross profit | $m | [1.3](/filings/0001213900-24-097450.md) | [0.0 d](/filings/0001013762-25-004072.md) | [2.3](/filings/0001213900-25-043287.md) | [1.2](/filings/0001213900-25-076635.md) | [1.6](/filings/0001437749-25-034817.md) | [2.8 d](/filings/0001437749-26-010339.md) | [3.4](/filings/0001437749-26-017045.md) | [2.8](/filings/0001437749-26-027668.md) | [2.4](/filings/0001437749-25-034817.md) | [2.9 d](/filings/0001437749-26-010339.md) | [4.7](/filings/0001437749-26-017045.md) | [2.4](/filings/0001437749-26-027668.md) |
| Research and development | $m | [1.1](/filings/0001213900-24-097450.md) | [0.0 d](/filings/0001013762-25-004072.md) | [1.3](/filings/0001213900-25-043287.md) | [1.0](/filings/0001213900-25-076635.md) | [0.8](/filings/0001437749-25-034817.md) | [0.8 d](/filings/0001437749-26-010339.md) | [0.8](/filings/0001437749-26-017045.md) | [0.8](/filings/0001437749-26-027668.md) | [0.7](/filings/0001437749-25-034817.md) | [0.8 d](/filings/0001437749-26-010339.md) | [0.3](/filings/0001437749-26-017045.md) | [0.1](/filings/0001437749-26-027668.md) |
| Operating income | $m | [(1.2)](/filings/0001213900-24-097450.md) | [0.0 d](/filings/0001013762-25-004072.md) | [(0.3)](/filings/0001213900-25-043287.md) | [(1.4)](/filings/0001213900-25-076635.md) | [(0.6)](/filings/0001437749-25-034817.md) | [0.6 d](/filings/0001437749-26-010339.md) | [1.1](/filings/0001437749-26-017045.md) | [0.6](/filings/0001437749-26-027668.md) | [0.0](/filings/0001437749-25-034817.md) | [(0.1) d](/filings/0001437749-26-010339.md) | [2.0](/filings/0001437749-26-017045.md) | [1.9](/filings/0001437749-26-027668.md) |
| Interest expense | $m | [0.1](/filings/0001213900-24-097450.md) | [0.2 d](/filings/0001213900-24-028718.md) | [0.1](/filings/0001213900-24-042925.md) | [0.1](/filings/0001213900-24-068245.md) | [0.1](/filings/0001213900-24-097450.md) | [0.1 d](/filings/0001437749-26-010339.md) | [0.1](/filings/0001437749-26-017045.md) | [0.1](/filings/0001437749-26-027668.md) | [0.1](/filings/0001437749-25-034817.md) | [0.1 d](/filings/0001437749-26-010339.md) | [0.1](/filings/0001437749-26-017045.md) | [0.1](/filings/0001437749-26-027668.md) |
| Income tax | $m | [0.0](/filings/0001213900-24-097450.md) | [0.0 d](/filings/0001013762-25-004072.md) | [0.0](/filings/0001213900-25-043287.md) | [0.0](/filings/0001213900-25-076635.md) | [0.0](/filings/0001437749-25-034817.md) | [0.0 d](/filings/0001437749-26-010339.md) | [0.0](/filings/0001437749-26-017045.md) | [0.0](/filings/0001437749-26-027668.md) | [0.0](/filings/0001437749-25-034817.md) | [0.0 d](/filings/0001437749-26-010339.md) | [0.0](/filings/0001437749-26-017045.md) | [0.0](/filings/0001437749-26-027668.md) |
| Net income | $m | [(0.9)](/filings/0001213900-24-097450.md) | [(1.1) d](/filings/0001013762-25-004072.md) | [(0.4)](/filings/0001213900-25-043287.md) | [(1.5)](/filings/0001213900-25-076635.md) | [(0.7)](/filings/0001437749-25-034817.md) | [0.5 d](/filings/0001437749-26-010339.md) | [1.4](/filings/0001437749-26-017045.md) | [0.5](/filings/0001437749-26-027668.md) | [(0.1)](/filings/0001437749-25-034817.md) | [(2.8) d](/filings/0001437749-26-010339.md) | [1.9](/filings/0001437749-26-017045.md) | [1.8](/filings/0001437749-26-027668.md) |
| Diluted EPS | $ per share | [(0.12)](/filings/0001213900-24-097450.md) | not reported | [(0.06)](/filings/0001213900-25-043287.md) | [(0.20)](/filings/0001213900-25-076635.md) | [(0.09)](/filings/0001437749-25-034817.md) | not reported | [0.16](/filings/0001437749-26-017045.md) | [0.06](/filings/0001437749-26-027668.md) | [(0.02)](/filings/0001437749-25-034817.md) | not reported | [0.21](/filings/0001437749-26-017045.md) | [0.20](/filings/0001437749-26-027668.md) |
| Basic EPS | $ per share | [(0.12)](/filings/0001213900-24-097450.md) | not reported | [(0.06)](/filings/0001213900-25-043287.md) | [(0.20)](/filings/0001213900-25-076635.md) | [(0.09)](/filings/0001437749-25-034817.md) | not reported | [0.16](/filings/0001437749-26-017045.md) | [0.06](/filings/0001437749-26-027668.md) | [(0.02)](/filings/0001437749-25-034817.md) | not reported | [0.21](/filings/0001437749-26-017045.md) | [0.20](/filings/0001437749-26-027668.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold, us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [2.0](/filings/0001213900-23-086092.md) | [1.0](/filings/0001213900-24-068245.md) | [1.0](/filings/0001213900-24-042925.md) | [1.3](/filings/0001213900-24-068245.md) | not reported | [3.8](/filings/0001437749-26-010339.md) | not reported | not reported | [3.9](/filings/0001437749-25-034817.md) | [3.8](/filings/0001437749-26-027668.md) | [6.8](/filings/0001437749-26-017045.md) | [8.9](/filings/0001437749-26-027668.md) |
| Current assets | $m | [12.0](/filings/0001213900-23-086092.md) | [11.5](/filings/0001013762-25-004072.md) | [11.3](/filings/0001213900-24-042925.md) | [10.8](/filings/0001213900-24-068245.md) | [13.9](/filings/0001213900-24-097450.md) | [15.0](/filings/0001437749-26-010339.md) | [15.9](/filings/0001213900-25-043287.md) | [17.1](/filings/0001213900-25-076635.md) | [16.8](/filings/0001437749-25-034817.md) | [16.9](/filings/0001437749-26-027668.md) | [18.9](/filings/0001437749-26-017045.md) | [21.1](/filings/0001437749-26-027668.md) |
| Total assets | $m | [44.5](/filings/0001213900-24-097450.md) | [43.8](/filings/0001437749-25-034817.md) | [43.1](/filings/0001213900-25-043287.md) | [41.9](/filings/0001213900-24-068245.md) | [44.4](/filings/0001437749-25-034817.md) | [45.1](/filings/0001437749-26-010339.md) | [45.6](/filings/0001437749-26-017045.md) | [42.5](/filings/0001437749-26-027668.md) | [45.7](/filings/0001437749-25-034817.md) | [42.5](/filings/0001437749-26-027668.md) | [44.1](/filings/0001437749-26-017045.md) | [46.6](/filings/0001437749-26-027668.md) |
| Current liabilities | $m | [3.3](/filings/0001213900-23-086092.md) | [4.2](/filings/0001013762-25-004072.md) | [4.2](/filings/0001213900-24-042925.md) | [4.6](/filings/0001213900-24-068245.md) | [4.5](/filings/0001213900-24-097450.md) | [4.4](/filings/0001437749-26-010339.md) | [3.9](/filings/0001213900-25-043287.md) | [4.4](/filings/0001213900-25-076635.md) | [4.0](/filings/0001437749-25-034817.md) | [4.0](/filings/0001437749-26-027668.md) | [3.9](/filings/0001437749-26-017045.md) | [4.4](/filings/0001437749-26-027668.md) |
| Total liabilities | $m | [18.5](/filings/0001213900-23-086092.md) | [18.8](/filings/0001013762-25-004072.md) | [18.4](/filings/0001213900-24-042925.md) | [18.4](/filings/0001213900-24-068245.md) | [18.0](/filings/0001213900-24-097450.md) | [17.6](/filings/0001437749-26-010339.md) | [16.6](/filings/0001213900-25-043287.md) | [16.9](/filings/0001213900-25-076635.md) | [15.9](/filings/0001437749-25-034817.md) | [15.5](/filings/0001437749-26-027668.md) | [15.0](/filings/0001437749-26-017045.md) | [15.3](/filings/0001437749-26-027668.md) |
| Long-term debt | $m | [12.3](/filings/0001213900-23-086092.md) | not reported | not reported | not reported | not reported | [9.0](/filings/0001437749-26-010339.md) | [10.2](/filings/0001213900-25-043287.md) | [8.3](/filings/0001213900-25-076635.md) | [7.9](/filings/0001437749-25-034817.md) | [7.5](/filings/0001437749-26-027668.md) | [7.1](/filings/0001437749-26-017045.md) | [6.8](/filings/0001437749-26-027668.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | [1.5](/filings/0001437749-26-010339.md) | not reported | [1.5](/filings/0001213900-25-076635.md) | [1.6](/filings/0001437749-25-034817.md) | [1.6](/filings/0001437749-26-027668.md) | [1.6](/filings/0001437749-26-017045.md) | [1.5](/filings/0001437749-26-027668.md) |
| Short-term borrowings | $m | not reported | [10.4](/filings/0001213900-24-068245.md) | [10.1](/filings/0001213900-24-042925.md) | [9.9](/filings/0001213900-24-068245.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [26.0](/filings/0001213900-24-097450.md) | [25.0](/filings/0001437749-26-010339.md) | [24.6](/filings/0001213900-25-076635.md) | [23.5](/filings/0001437749-25-034817.md) | [26.4](/filings/0001437749-25-034817.md) | [27.5](/filings/0001437749-26-027668.md) | [29.0](/filings/0001437749-26-027668.md) | [29.9](/filings/0001437749-26-027668.md) | [29.8](/filings/0001437749-25-034817.md) | [27.1](/filings/0001437749-26-027668.md) | [29.1](/filings/0001437749-26-027668.md) | [31.4](/filings/0001437749-26-027668.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt, us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(508) d](/filings/0001213900-24-097450.md) | [(723) d](/filings/0001013762-25-004072.md) | [419](/filings/0001213900-25-043287.md) | [582 d](/filings/0001213900-25-076635.md) | [(639) d](/filings/0001437749-25-034817.md) | [(3.1) d](/filings/0001437749-26-010339.md) | [1,574](/filings/0001437749-26-017045.md) | [1,601 d](/filings/0001437749-26-027668.md) | [(1,183) d](/filings/0001437749-25-034817.md) | [483 d](/filings/0001437749-26-010339.md) | [3,573](/filings/0001437749-26-017045.md) | [3,019 d](/filings/0001437749-26-027668.md) |
| Capital expenditure | $k | [421 d](/filings/0001213900-24-097450.md) | [81.3 d](/filings/0001013762-25-004072.md) | [70.4](/filings/0001213900-25-043287.md) | [111 d](/filings/0001213900-25-076635.md) | [88.4 d](/filings/0001437749-25-034817.md) | [196 d](/filings/0001437749-26-010339.md) | [329](/filings/0001437749-26-017045.md) | [155 d](/filings/0001437749-26-027668.md) | [594 d](/filings/0001437749-25-034817.md) | [172 d](/filings/0001437749-26-010339.md) | [177](/filings/0001437749-26-017045.md) | [734 d](/filings/0001437749-26-027668.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [7,747](/filings/0001213900-23-086092.md) | [7,747](/filings/0001213900-24-042925.md) | [7,747](/filings/0001213900-24-068245.md) | [7,747](/filings/0001213900-24-097450.md) | [7,751](/filings/0001213900-25-043287.md) | [7,810](/filings/0001213900-25-076635.md) | [8,164](/filings/0001437749-25-034817.md) | [8,981](/filings/0001437749-26-017045.md) | [9,031](/filings/0001437749-26-027668.md) | [9,046](/filings/0001437749-25-034817.md) | [9,046](/filings/0001437749-26-017045.md) | [9,189](/filings/0001437749-26-027668.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 9,082,197 at 2026-07-31, from the cover of the [10-Q filed 2026-08-13](/filings/0001437749-26-027668.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:25 ET. No prices; not investment advice.